โ† All deals

Linnaeus Therapeutics, Inc.

BiotechnologyBiotechnologyOncologyClinical-stage
๐Ÿ“ Haddonfield, New Jersey, United Statesโ€ข Founded 2016โ€ข 2-10 employees
StreetZero Signal 74
Be the first to signal interest

About Linnaeus Therapeutics, Inc.

Linnaeus Therapeutics, Inc. is a privately held, clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel small-molecule therapeutics targeting G protein-coupled receptors. The company was founded in 2016 based on discoveries originating at the University of Pennsylvania and launched in partnership with the UPstart incubator at Penn Center for Innovation. It is advancing its lead compound LNS8801 across oncology and healthspan-related indications, with headquarters in Haddonfield, New Jersey.

LATEST FUNDINGPrivate Placement
$3.7M
Announced 2026-11-18
TOTAL RAISED$34.75M
๐Ÿ”’

Unlock the full deal profile

Create a free account to see investors, key highlights, news, company details and the AI analysis for Linnaeus Therapeutics, Inc..

Free plan includes 3 full deal profiles every month.

Key highlights

  • Closed nearly $4.5M addition to Series B to fund next clinical trial and team expansion.
  • Awarded up to $22M from ARPA-H to advance LNS8801 for healthspan preservation.
  • Lead compound LNS8801 targets GPER for oncology indications with orphan drug and Fast Track status.
  • Founded on University of Pennsylvania discoveries and supported by Penn Medicine Co-Investment Fund.
  • Total funding reported at approximately $35M with additional non-dilutive grants from NCI and SBIR.

Source document & SEC filing

The source SEC filing and the cached document are available to members only. Sign in to view and download them.

Sign in to view the filing Create free account